glp 1 news A wave of new #GLP1 drug options for type 2 #Diabetes and #Obesity was a major focus at #ADA2026. In the latest JAMA Medical podcast, Jennifer Abbasi interviews Rita Kalyani, MD Jim Cramer dissects how GLP-1

Individuals with lower socioeconomic status and those from under-served and minority communities are more likely to have obesity and obesity-related complications than those from higher socioeconomic status or those from privileged and/or majority groups

Teaming up with researchers in Copenhagen, they showed that a PAM defect does not alter the GLP-1 receptors ability to bind GLP-1, nor how the hormone signals through the receptor

Patients often report nausea, vomiting, bloating, or bowel changes early in treatment

This growing role makes it essential for NPs to understand the full scope of GLP-1RA indications, benefits, and risks to ensure safe, effective, and equitable care

This is significant news because diabetes often leads to kidney damage over time

Compounding the problem is the fact that insurance companies are reluctant to cover these anti-obesity medications, since theyre considered by many to be vanity drugs, even though overwhelming evidence suggests obesity is linked directly to multiple comorbidities